Caroline Dive | Academic Influence

Caroline Dive's AcademicInfluence.com Rankings

Caroline Dive

Medical

#1263

World Rank

#1583

Historical Rank

Pharmacology

#143

World Rank

#179

Historical Rank

medical Degrees

Download Badge

Medical

Caroline Dive's Degrees

Bachelors Biochemistry University of Oxford

Why Is Caroline Dive Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Caroline Dive is a British cancer research scientist. Dive is Professor of Cancer Pharmacology at the University of Manchester, Deputy Director of the Cancer Research UK Manchester Institute, Director of the CRUK Manchester Institute Cancer Biomarker Centre and co-director of the CRUK Lung Cancer Centre of Excellence. She is the current President of The European Association for Cancer Research .

(See a Problem?)

Caroline Dive's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Tracking the Evolution of Non‐Small‐Cell Lung Cancer (2017) (1525)
Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. (1993) (1209)
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution (2017) (1092)
Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. (2011) (788)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution (2017) (772)
Imaging biomarker roadmap for cancer studies (2016) (718)
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. (2012) (690)
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer (2014) (597)
Biological mechanisms linking obesity and cancer risk: new perspectives. (2010) (586)
Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. (1992) (585)
Activation of Epstein–Barr virus latent genes protects human B cells from death by apoptosis (1991) (545)
Molecular analysis of circulating tumour cells—biology and biomarkers (2014) (539)
Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis (1999) (533)
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. (2011) (512)
Progress and prospects of early detection in lung cancer (2017) (490)
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data (2019) (485)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer (2012) (442)
Drug-target interactions: only the first step in the commitment to a programmed cell death? (1991) (436)
Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches (2012) (402)
Circulating tumor cells as a window on metastasis biology in lung cancer. (2011) (399)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies (2018) (376)
Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance (2004) (375)
Requirement of basement membrane for the suppression of programmed cell death in mammary epithelium. (1996) (299)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors (2017) (292)
Role of mitochondrial membrane permeabilization in apoptosis and cancer (2004) (284)
Obesity and cancer: pathophysiological and biological mechanisms. (2008) (264)
bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. (1993) (262)
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. (2016) (259)
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker (2011) (246)
Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer (2016) (245)
Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer (2013) (244)
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. (2009) (238)
Circulating tumour cells: their utility in cancer management and predicting outcomes (2010) (232)
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors (2009) (212)
Extracellular Matrix Regulates Apoptosis in Mammary Epithelium through a Control on Insulin Signaling (1999) (209)
Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study (2014) (208)
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial (2015) (205)
Mitochondrial membrane permeabilisation by Bax/Bak. (2003) (202)
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer (2010) (198)
Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin (1994) (197)
Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. (2016) (189)
Vasculogenic mimicry in small cell lung cancer (2016) (174)
Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance. (2020) (172)
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study (2019) (171)
Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. (1993) (169)
Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. (1993) (162)
Damage‐induced Bax N‐terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate (2001) (142)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (141)
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? (2016) (141)
Obesity and cancer: Pathophysiological and biological mechanisms (2008) (136)
Biomarker method validation in anticancer drug development (2008) (133)
Bid, a Widely Expressed Proapoptotic Protein of the Bcl-2 Family, Displays Lipid Transfer Activity (2001) (132)
Proapoptotic Bid binds to monolysocardiolipin, a new molecular connection between mitochondrial membranes and cell death (2003) (131)
Induction of apoptosis--new targets for cancer chemotherapy. (1992) (131)
Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. (2013) (127)
Apoptosis and cancer chemotherapy. (2001) (120)
Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with small-cell lung cancer. (2011) (120)
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2019) (119)
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2019) (119)
Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. (1998) (117)
Biomarkers of apoptosis (2008) (114)
Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs (2010) (111)
PCAF is an HIF-1α cofactor that regulates p53 transcriptional activity in hypoxia (2008) (111)
Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. (1996) (111)
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2019) (110)
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (2020) (109)
Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer (2008) (108)
Characterization of cell volume loss in CEM-C7A cells during dexamethasone-induced apoptosis. (1996) (107)
Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death (2009) (106)
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer (2018) (105)
External quality assurance of circulating tumor cell enumeration using the CellSearch® system: A feasibility study (2011) (105)
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study (2009) (104)
Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. (2000) (103)
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial (2015) (99)
How liquid biopsies can change clinical practice in oncology. (2019) (95)
Flow Cytometry and Sorting (1991) (94)
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. (2009) (92)
Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. (2016) (91)
Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP (2005) (91)
Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak (2001) (88)
Chronic hypoxia promotes hypoxia-inducible factor-1α–dependent resistance to etoposide and vincristine in neuroblastoma cells (2006) (87)
Apoptosis pathway-targeted drugs--from the bench to the clinic. (2004) (85)
Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. (1994) (81)
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity (2020) (81)
Optimisation of circulating biomarkers of cell death for routine clinical use. (2008) (81)
How liquid biopsies can change clinical practice in oncology. (2019) (80)
Quantitative mass spectrometry-based techniques for clinical use: Biomarker identification and quantification☆ (2008) (79)
IAPs as a target for anticancer therapy. (2007) (78)
Multiplexed assays for detection of mutations in PIK3CA. (2008) (78)
Post-translational Modification of Bid Has Differential Effects on Its Susceptibility to Cleavage by Caspase 8 or Caspase 3* (2003) (78)
Comparison of doxycycline delivery methods for Tet-inducible gene expression in a subcutaneous xenograft model. (2007) (77)
Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer (2010) (77)
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity (2006) (76)
Consensus on precision medicine for metastatic cancers: a report from the MAP conference. (2016) (75)
Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP (2006) (74)
DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer (2007) (73)
Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample (2015) (73)
Hypoxia–Induced Cytotoxic Drug Resistance in Osteosarcoma Is Independent of HIF-1Alpha (2013) (72)
Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study (2016) (71)
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. (2008) (71)
Early detection of cancer (2022) (70)
Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC (2016) (70)
Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis. (1995) (68)
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma (2021) (68)
Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma (2014) (67)
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity (2008) (66)
The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer (2014) (63)
Quantitative multiplexed quantum dot immunohistochemistry. (2008) (62)
Circulating biomarkers in hepatocellular carcinoma (2014) (62)
Circulating tumor cells and CDX models as a tool for preclinical drug development. (2017) (62)
Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells. (1995) (61)
Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’ (2018) (60)
New approaches to small cell lung cancer therapy : from the laboratory to the clinic. (2020) (60)
Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells. (1997) (60)
Expression of Kinase-defective Mutants of c-Src in Human Metastatic Colon Cancer Cells Decreases Bcl-xL and Increases Oxaliplatin- and Fas-induced Apoptosis* (2004) (59)
Blood cells with reduced mitochondrial membrane potential and cytosolic cytochrome C can survive and maintain clonogenicity given appropriate signals to suppress apoptosis. (1998) (59)
A clonal expression biomarker associates with lung cancer mortality (2019) (59)
The T cell differentiation landscape is shaped by tumour mutations in lung cancer (2020) (59)
Polar fluorescein derivatives as improved substrate probes for flow cytoenzymological assay of cellular esterases. (1988) (58)
Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. (2016) (57)
SnapShot: Circulating Tumor Cells (2017) (57)
Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. (2007) (57)
Non-genotoxic hepatocarcinogenesis in vitro: the FaO hepatoma line responds to peroxisome proliferators and retains the ability to undergo apoptosis. (1993) (56)
Statistical Considerations of Optimal Study Design for Human Plasma Proteomics and Biomarker Discovery (2012) (54)
Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells. (1994) (53)
Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma (2014) (53)
EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. (2019) (52)
Circulating Tumor Cells, Enumeration and Beyond (2010) (52)
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer (2010) (51)
Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. (2011) (51)
X-linked inhibitor of apoptosis protein as a therapeutic target (2007) (50)
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA (2016) (50)
MCF‐7 human mammary adenocarcinoma cell death in vitro in response to hormone‐withdrawal and dna damage (1995) (50)
Suppression of apoptosis by v-ABL protein tyrosine kinase is associated with nuclear translocation and activation of protein kinase C in an interleukin-3-dependent haemopoietic cell line. (1995) (49)
Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells (2009) (48)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC). (2019) (48)
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma (2011) (48)
An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. (2014) (47)
The suppression of drug-induced apoptosis by activation of v-ABL protein tyrosine kinase. (1994) (47)
Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy? (2001) (47)
Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. (2015) (47)
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours (2010) (46)
PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways (2017) (46)
Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma (2007) (45)
Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. (2012) (45)
Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system. (2014) (45)
Fit-for-purpose biomarker method validation in anticancer drug development. (2010) (44)
Will liquid biopsies improve outcomes for patients with small-cell lung cancer? (2018) (44)
Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. (2015) (43)
The non-genotoxic hepatocarcinogen nafenopin suppresses rodent hepatocyte apoptosis induced by TGFbeta1, DNA damage and Fas. (1998) (43)
A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC (2009) (42)
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer (2017) (42)
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial (2018) (42)
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies (2015) (42)
Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models (2017) (40)
Protein Z: A putative novel biomarker for early detection of ovarian cancer (2016) (40)
Multiparametric analysis of cell membrane permeability by two colour flow cytometry with complementary fluorescent probes. (1990) (40)
The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report (2020) (39)
Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC (2020) (39)
Role of acid/base homeostasis in the suppression of apoptosis in haemopoietic cells by v-Abl protein tyrosine kinase. (1997) (38)
Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation (2000) (37)
Comparison of phosphatidylinositol‐3‐kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild‐type PIK3CA (2005) (37)
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells. (2007) (37)
Targeting DNA damage in SCLC. (2017) (36)
Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. (2003) (35)
v-Abl protein tyrosine kinase (PTK) mediated suppression of apoptosis is associated with the up-regulation of Bcl-XL (1997) (35)
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer (2019) (35)
'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. (2009) (35)
Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer (2018) (35)
Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients (2013) (34)
803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC) (2011) (34)
Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents. (2011) (33)
Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer (2012) (33)
Liquid chromatography-mass spectrometry calibration transfer and metabolomics data fusion. (2012) (33)
Avoidance of apoptosis as a mechanism of drug resistance (1997) (32)
Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase. (1995) (31)
A caspase-3 ‘death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers (2013) (31)
Survival signals within the tumour microenvironment suppress drug-induced apoptosis: lessons learned from B lymphomas. (1999) (31)
Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers. (2013) (31)
Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. (2020) (31)
Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis. (1995) (30)
Quantification of skeletal metastases in castrate‐resistant prostate cancer predicts progression‐free and overall survival (2014) (30)
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours (2013) (30)
Circulating Biomarkers of Cell Death After Treatment with the BH-3 Mimetic ABT-737 in a Preclinical Model of Small-Cell Lung Cancer (2008) (30)
Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. (2010) (30)
Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. (2011) (30)
Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors (2010) (30)
Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC (2016) (29)
Increases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo. (2006) (28)
Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics (2018) (28)
Generation of cells expressing improved doxycycline-regulated reverse transcriptional transactivator rtTA2S-M2 (2006) (28)
A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients (2012) (27)
The Novel Bcl-2 Inhibitor ABT-737 Is More Effective in Hypoxia and Is Able to Reverse Hypoxia-Induced Drug Resistance in Neuroblastoma Cells (2011) (27)
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. (2010) (25)
Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. (2010) (25)
DNA-damaging agents induce both p53-dependent and p53-independent apoptosis in immature thymocytes. (1996) (25)
Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells. (1991) (25)
Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value (2015) (24)
Blocking Phosphoinositide 3-Kinase Activity in Colorectal Cancer Cells Reduces Proliferation but Does Not Increase Apoptosis Alone or in Combination with Cytotoxic Drugs (2009) (24)
Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer (2019) (24)
Towards a cancer mission in Horizon Europe: recommendations (2020) (24)
Improved methodology for intracellular enzyme reaction and inhibition kinetics by flow cytometry. (1987) (24)
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial (2019) (23)
Changes in intercellular junctions during apoptosis precede nuclear condensation or phosphatidylserine exposure on the cell surface (2000) (23)
Clinical Evaluation of M 30 and M 65 ELISA Cell Death Assays as Circulating Biomarkers in a Drug-Sensitive Tumor , Testicular Cancer 1 (2008) (23)
The clinical utility of circulating tumour cells in patients with small cell lung cancer. (2017) (23)
BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737. (2014) (23)
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab (2016) (23)
Comparative effects of Bcl-2 over-expression and ZVAD.FMK treatment on dexamethasone and VP16-induced apoptosis in CEM cells (1998) (23)
Hypoxia-driven splicing into noncoding isoforms regulates the DNA damage response (2016) (22)
twoddpcr: an R/Bioconductor package and Shiny app for Droplet Digital PCR analysis (2017) (22)
A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours (2006) (22)
Expression of pro‐apoptotic Bfk isoforms reduces during malignant transformation in the human gastrointestinal tract (2005) (22)
Circulating tumour DNA — looking beyond the blood (2022) (21)
In silico screening and biological evaluation of inhibitors of Src-SH3 domain interaction with a proline-rich ligand. (2008) (21)
Construction and characterization of multiple human colon cancer cell lines for inducibly regulated gene expression (2005) (21)
Clinical Utility of Circulating Tumour Cell Detection in Non-Small-Cell Lung Cancer (2013) (21)
Development of a circulating miRNA assay to monitor tumor burden: From mouse to man (2015) (21)
A proof‐of‐principle gel‐free proteomics strategy for the identification of predictive biomarkers for the onset of pre‐eclampsia (2009) (21)
Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories (2020) (21)
Small cell lung cancer enters the era of precision medicine. (2021) (20)
Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain (2006) (20)
Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells (2014) (20)
Novel dynamic flow cytoenzymological determination of intracellular esterase inhibition by BCNU and related isocyanates. (1987) (20)
Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution (2017) (20)
Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix (2005) (19)
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. (2011) (19)
Using DNA sequencing data to quantify T cell fraction and therapy response (2021) (19)
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial (2018) (19)
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial (2012) (18)
Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response (2013) (18)
Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker. (2009) (18)
Method validation of circulating tumour cell enumeration at low cell counts (2013) (17)
Effect of prolonged formalin fixation on immunohistochemical staining for the proliferation marker Ki67 (2011) (17)
Early Dissemination of Circulating Tumor Cells: Biological and Clinical Insights (2021) (17)
Identification of a Biomarker Panel for Early Detection of Lung Cancer Patients. (2019) (17)
Application of sequencing, liquid biopsies and patient-derived xenografts for personalized medicine in melanoma (2016) (16)
Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data (2019) (16)
Diagnostic Mutation Profiling and Validation of Non–Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform (2015) (16)
Protein kinase C delta is phosphorylated on five novel Ser/Thr sites following inducible overexpression in human colorectal cancer cells (2007) (16)
Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging (2017) (15)
Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs (2010) (15)
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial. (2019) (15)
Somatically mutated ABL1 is an actionable and essential NSCLC survival gene (2016) (15)
A hierarchical statistical modeling approach to analyze proteomic isobaric tag for relative and absolute quantitation data (2014) (15)
Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. (2015) (15)
Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells (2014) (15)
Biomarkers of cell death applicable to early clinical trials. (2012) (15)
[18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941 (2013) (15)
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. (2020) (14)
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer (2022) (14)
Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy (2010) (14)
Novel risk models for early detection and screening of ovarian cancer (2016) (14)
cfDNA methylome profiling for detection and subtyping of small cell lung cancers (2022) (14)
Obesity, insulin and chemoresistance in colon cancer. (2011) (13)
Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours (2009) (13)
The rodent non-genotoxic hepatocarcinogen nafenopin suppresses apoptosis preferentially in non-cycling hepatocytes but also elevates CDK4, a cell cycle progression factor. (1998) (13)
Molecular analysis of single circulating tumour cells following long‐term storage of clinical samples (2017) (12)
Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5‐year results from a UK National Cancer Research Institute Lymphoma Group study (2016) (12)
Reciprocal relationship between expression of hypoxia inducible factor 1α (HIF-1α) and the pro-apoptotic protein Bid in ex vivo colorectal cancer (2008) (12)
LBA25_PRCIRCCA: A RANDOMISED DOUBLE BLIND PHASE II TRIAL OF CARBOPLATIN-PACLITAXEL PLUS CEDIRANIB VERSUS CARBOPLATIN-PACLITAXEL PLUS PLACEBO IN METASTATIC/RECURRENT CERVICAL CANCER. (CRUK GRANT REF: C1256/A11416) (2014) (11)
A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity (2013) (10)
A conserved YAP/Notch/REST network controls the neuroendocrine cell fate in the lungs (2022) (10)
Cell cycle specific induction of HL-60 cell differentiation and apoptosis by mycophenolic acid (1997) (10)
Cytoplasmic acidification is not an effector mechanism of VP16 or DEX-induced apoptosis in CEM T leukaemia cells. (1999) (10)
A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors. (2006) (10)
Application of the β-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays. (2011) (10)
Mechanisms of Apoptosis (1997) (10)
Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells (2015) (9)
Evaluation of apoptosis imaging biomarkers in a genetic model of cell death (2019) (9)
Inhibition of intracellular esterases by antitumour chloroethylnitrosoureas. Measurement by flow cytometry and correlation with molecular carbamoylation activity. (1988) (9)
Chapter 31 Enzyme Kinetics (1994) (9)
Both stromal cell and colonocyte epidermal growth factor receptors control HCT116 colon cancer cell growth in tumor xenografts. (2012) (9)
Identification and targeting of long-term tumor-propagating cells in small cell lung cancer (2016) (9)
Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer (2021) (8)
Expanding therapeutic opportunities for Extra-Pulmonary Neuroendocrine Carcinoma. (2022) (8)
CIRCULATING TUMOR CELLS AS TUMOR BIOMARKERS IN MELANOMA : DETECTION METHODS AND CLINICAL RELEVANCE (2014) (8)
Immunotherapy in small cell lung cancer (2016) (8)
The biomolecule corona of lipid nanoparticles contains circulating cell-free DNA. (2020) (8)
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome (2022) (7)
The development of composite circulating biomarker models for use in anticancer drug clinical development (2011) (7)
External Quality Assurance of Circulating Tumor Cell Enumeration Using (2011) (7)
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin (2018) (7)
Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants. (2020) (7)
The evolution of lung cancer and impact of subclonal selection in TRACERx (2023) (7)
Abstract 4294: GE152:In vivodetection of tumor apoptosis as a tool for assessment of therapeutic efficacy (2012) (7)
ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC). (2014) (6)
Genomic–transcriptomic evolution in lung cancer and metastasis (2023) (6)
Preclinical evaluation of M 30 and M 65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity (2008) (6)
ERS is founding member of a new Alliance for Biomedical Research in Europe (2011) (6)
PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology. (2016) (6)
The evolution of non-small cell lung cancer metastases in TRACERx (2023) (6)
Control of apoptosis in breast epithelium (1997) (6)
Tetracycline Regulated Systems in Functional Oncogenomics (2007) (5)
Flow cytometric analysis of steroidogenic organelles in differentiating granulosa cells. (1992) (5)
iRFP (near-infrared fluorescent protein) imaging of subcutaneous and deep tissue tumours in mice highlights differences between imaging platforms (2021) (5)
Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: a short communication. (2013) (5)
In silico error correction improves cfDNA mutation calling (2018) (5)
Early Adaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associated with Activation of “Stemness” Programs and Local Inflammation (2020) (5)
Final results of a phase I clinical trial of the bioreductive drug RH1 (2007) (5)
Biology and clinical relevance of circulating tumour cells. (2012) (5)
Synchronous apoptosis in established tumors leads to the induction of adaptive immunity (2013) (5)
ABC-03: A randomized, phase II/III study of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine for patients with advanced biliary tract cancers. (2010) (5)
1628O Development of the Manchester Cancer Research Centre Molecular Tumour Board for matching patients to clinical trials based on tumour and ctDNA genetic profiling. (2017) (4)
v-Abl Protein-tyrosine Kinase Up-regulates p21WAF-1 in Cell Cycle Arrested and Proliferating Myeloid Cells* (2001) (4)
Over-expression of activated c-Src in ductal carcinoma in situ predicts disease recurrence at 5 years and correlates with her2 positivity, high tumour grade, comedo histologic type and high proliferation (2006) (4)
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA (2023) (4)
The role of the extracellular matrix and lactogenic hormones in mammary gland apoptosis. (1996) (4)
1: Circulating tumour cells from small cell lung cancer patients are tumourigenic (2015) (4)
TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change (2021) (4)
CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma. (2021) (4)
Apoptosis in Hematopoiesis and Leukemogenesis (1996) (4)
EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer (2021) (3)
A phase Ib and randomised phase II trial of pazopanib with or without fosbretabulin in advanced recurrent ovarian cancer. (2018) (3)
OA05.07 Prognostic Value of Circulating Tumor Cells in Limited-Disease Small Cell Lung Cancer Patients Treated on the CONVERT Trial (2017) (3)
TARGET trial: Molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials. (2016) (3)
Cancer Moonshot Connecting International Liquid Biopsy Efforts Through Academic Partnership (2017) (3)
Antibodies against endogenous retroviruses promote lung cancer immunotherapy (2023) (3)
Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry (2004) (3)
The TARGET trial: Molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials (2016) (3)
Lung adenocarcinoma promotion by air pollutants (2023) (3)
Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial. (2019) (3)
Circulating Tumour Cells (2017) (3)
CIRCULATING TUMOR CELLS (2012) (3)
The application of liquid biopsies in metastatic salivary gland cancer to identify candidate therapeutic targets. (2017) (3)
Is metabolism an important arbiter of anticancer activity of ether lipids? metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites (2004) (3)
Pro-opiomelanocortin is a novel biomarker for small cell lung cancer (2010) (3)
Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2020) (3)
Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2020) (3)
Serum Biomarkers of Apoptosis (2007) (3)
SnapShot: Circulating Tumor Cells. (2017) (3)
CORONET; COVID-19 in Oncology evaluatiON Tool: Use of machine learning to inform management of COVID-19 in patients with cancer. (2021) (3)
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital (2022) (3)
Circulating tumor cell eXplants (CDX) to advance small cell lung cancer (SCLC) research and drug development (2016) (2)
Medical societies unite to support research in Europe (2011) (2)
Characterization of Cell Volume Loss during Dexamethasone-Induced Apoptosis (1995) (2)
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay (2022) (2)
Measurement of Enzyme Kinetics by Flow Cytometry (1993) (2)
Difluoro analogue of UCS15A triggers activation of exogenously expressed c-Src in HCT 116 human colorectal carcinoma cells (2007) (2)
Can flow cytoenzymology be applied to measure membrane-bound enzyme kinetics? Assessment by analysis of gamma-glutamyl transpeptidase activity. (1993) (2)
The role of vasculogenic mimicry in small cell lung cancer (2016) (2)
A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma. (2016) (2)
Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection (2021) (2)
Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2020) (2)
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves (2022) (2)
Bax, Bak and Bid: Key Mediators of Apoptosis (2008) (2)
Circulating Melanoma Cells (CMCS) in Mucosal and Uveal Melanomas (2012) (2)
Alliance for biomedical research in Europe (2011) (2)
Abstract 3371: Genetic, phenotypic and functional characterisation of vasculogenic mimicry in small-cell lung cancer (2016) (1)
Abstract 3098: The first circulating tumor cell-derived explant (CDX) model of a Merkel cell carcinoma (2022) (1)
INTERACTIONS OF THE PHOSPHORUS ANALOGUE OF OXALOACETATE AND THE ARSENIC ANALOGUE OF MALATE WITH MALATE DEHYDROGENASE (1990) (1)
Abstract 2653: Lineage plasticity in small cell lung cancer generates non- neuroendocrine cells primed for vascular mimicry (2021) (1)
Detection of circulating tumor cells in uveal melanoma using the CellSearch® system (2013) (1)
Assessment Of Circulating Free DNA (CFDNA) and Circulating Melanoma Cells (CMCS) as Prognostic Biomarkers in Metastatic Cutaneous Melanoma (2012) (1)
Gastrointestinal tumors, colorectal (2012) (1)
Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II). (2017) (1)
Abstract 5601: Single-cell molecular profiling of circulating tumor cells (CTCs) within the TRACERx study reveals heterogeneous patterns in early non-small cell lung cancer (NSCLC) (2018) (1)
A NOVEL TRIAL DESIGN FOR RECTAL CANCER: THE DREAMtherapy TRIAL (Dual REctal Angiogenesis MEK inhibition radioTherapy) (2011) (1)
Cell Sensitivity Assays : Detection of Apoptotic Cells In Vitro Using the TUNEL Assay. (1999) (1)
Damage-induced Bax N-terminal change and translocation to mitochondria occur regardless of cell fate (2001) (1)
Enzyme kinetics. (1994) (1)
Dynamics of circulating vascular endothelial growth factor‐A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients (2019) (1)
467PFGFR INHIBITOR AND CHEMOTHERAPY IN GASTRIC CANCER (FACING): PHASE I RESULTS FROM AN ECMC COMBINATIONS ALLIANCE PHASE I/II TRIAL OF AZD4547 IN COMBINATION WITH CISPLATIN AND CAPECITABINE (CX). (2014) (1)
Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer (2018) (1)
Utility of circulating biomarkers of cell death in disseminated testicular cancer patients treated with standard platinum-based chemotherapy (2007) (1)
Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours. (2007) (1)
Evolutionary characterisation of lung adenocarcinoma morphology in TRACERx (2023) (1)
Abstract 5602: Detection of circulating cell-free tumor DNA (ctDNA) in patients with small cell lung cancer (SCLC) (2018) (1)
Abstract 80: Programmatic re-splicing of the hypoxia transcriptome regulates the DNA damage response (2016) (1)
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial (2018) (1)
182 Do circulating tumour cell (CTC) counts correlate with tumour volume in limited disease small cell lung cancer (LD-SCLC)? An exploratory clinical study with survival outcomes (2012) (1)
Enrichment and Purification of CTCs. How and Why (2013) (1)
A model of k-mer surprisal to quantify local sequence information content surrounding splice regions (2020) (1)
The control of apoptosis through cell-stromal interactions (1998) (1)
Ex vivo culture of circulating tumour cell derived explants to facilitate rapid therapy testing in small cell lung cancer (2016) (1)
PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways (2017) (1)
9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994) (2020) (1)
Updated results of a phase I study to investigate dose escalation of doxorubicin in cycles 1-3 of ABVD chemotherapy for Hodgkin lymphoma and to correlate this with blood-borne biomarkers of tumour response and toxicity (2011) (1)
EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer. (2019) (1)
Molecular Characterisation of SCLC Using Both Circulating Tumour DNA and Circulating Tumour Cells Isolated from the Same preserved whole blood sample (2015) (1)
Method validation of circulating tumour cell enumeration at low cell counts (2013) (1)
Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study (2020) (1)
Abstract 5685: An evaluation of DNA and RNA based blood biomarkers in prostate cancer (2017) (1)
469 POSTER Detection of surrogate markers of apoptosis in the peripheral blood of a preclinical tumour model treated with a selective inhibitor of Aurora B kinase (AZD1152) (2006) (1)
Abstract 2432: A technology platform for personalized medicine in melanoma (2015) (0)
Circulating Melanoma Cells (CMCs), End of a Stalemate (2011) (0)
Abstract CN08-03: Liquid biopsies for the management of cancer patient treatment and for early detection of cancer (2018) (0)
Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data (2019) (0)
Abstract 5434: Inhibition of monocarboxylate transporter 1 as a therapeutic strategy in small cell lung cancer: target validation studies using the MCT1 inhibitor AZD3965. (2013) (0)
Acknowledgments (2012) (0)
Abstract 3960: Combined circulating tumour cell (CTC) and circulating tumor DNA (ctDNA) analysis of blood from patients with pancreatic cancer (2016) (0)
Abstract 2360: The role of the neurogenic transcription factor ATOH1 in small cell lung cancer (2022) (0)
MS 15.03 Molecular Testing Using Blood (Liquid Biopsy) (2017) (0)
731P Multi-maintenance olaparib in relapsed, platinum-sensitive BRCA-mutant high-grade serous ovarian carcinoma (MOLTO): A phase II feasibility study (2021) (0)
非遺伝毒性性肝癌発症物質ナフェノピンは,TGF-β1,DNA損傷剤またはFas誘発性の,げっ歯類肝細胞におけるアポトーシスの発現を抑制する (1998) (0)
Pharmacodynamic study of antiangiogenic therapy in patients with renal cell carcinoma. (2011) (0)
Abstract 5948: Modeling lung squamous cell carcinoma progression using primary human bronchial basal cells (2022) (0)
Molecular profiling of tumour and ctDNA in a gastrointestinal cancer cohort at an academic cancer centre. (2018) (0)
Running title: Integrated assessment of doxorubicin cardiotoxicity (2014) (0)
Body composition and lung cancer-associated cachexia in TRACERx (2023) (0)
– Prostate Cancer Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and-nonvisible Lesions in Clinically Localised Prostate Cancer (2018) (0)
Circulating Tumor Cells and Lung Cancer, Utility Beyond Prognosis? (2014) (0)
Molecular analysis of circulating free nucleic acids and CTC genomes in patients with pancreatic adenocarcinoma (2016) (0)
87P Assessment of the prognostic utility of the enumeration of circulating tumour cells at the end of treatment and disease relapse in small cell lung cancer patients (2018) (0)
Abstract 2436: Heterogeneity of neurogenic transcription factor expression in small cell lung cancer (2021) (0)
P1.04-43 PD-RAD: A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-Small Cell Lung Cancer - Trial in Progress (2019) (0)
MS12.01 Circulating Biomarkers (2019) (0)
Abstract 1022: PI3-kinase inhibition enhances ABT-737-induced apoptosis in colorectal cancer cell lines (2010) (0)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (0)
59: CTCs and cfDNA, will they be useful for early detection of cancer? (2014) (0)
32 Circulating Tumour Cells, Utility Beyond Prognosis? (2012) (0)
be 1-2 Modulation of Apoptosis Induced by Anticancer Drugs : Resistance to Thymidylate Stress Is Independent of Classical Resistance Pathways 1 (2006) (0)
Targeting Bcl-2 Family Proteins in Childhood Leukemia (2011) (0)
Abstract 1468: Circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) from patients with small cell lung cancer (SCLC) show heterogeneity in epithelial to mesenchymal transition (EMT) phenotype and evidence of vasculogenic mimicry (VM). (2013) (0)
Circulating tumour cells as liquid biopsies in clinical studies: the example of TRACERx. (2018) (0)
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study (2019) (0)
199 Pulmonary vein circulating tumour cells from patients undergoing curative resection of non-small cell lung cancer (2012) (0)
Abstract 2808: cfDNA multi-omics profiling and tissue of origin predictions in cancers of unknown primary (2022) (0)
An inducible caspase-3 “tumor death switch” model to identify circulating biomarkers of apoptotic cell death and test novel imaging probes for apoptosis. (2007) (0)
An open source R package for Droplet Digital PCR analysis (2016) (0)
Investigating the impact of PI3-kinase inhibition on colorectal cancer cell growth and responsive to Oxaliplatin using an inducible genetic model. (2007) (0)
Novel Cardiac MRI and Circulating Biomarkers Model of Anthracycline-induced Cardiotoxicity suggests that "Healthier Heart" may be at Greatest Risk (2015) (0)
Clinical utility of blood-borne markers of epithelial cell death in pancreatic cancer (2008) (0)
Hypoxia increases the sensitivity of small cell lung cancer, colorectal cancer and neuroblastoma cells to the BH-3 mimetic ABT-737 (2007) (0)
Abstract 3143: Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: correlative study of AZD9496 oral SERD phase I trial (2021) (0)
Triple wild-type' co-mutational profile in early-stage KRAS-mutant lung cancer (2020) (0)
Inter-tumor validation, through advanced MRI and circulating biomarkers, of plasma Tie2 as the vascular response biomarker for bevacizumab. (2017) (0)
AEG-35156 (2009) (0)
Cancer Therapy : Clinical Phase II Study of Single-Agent Navitoclax ( ABT-263 ) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer (2012) (0)
Circulating tumour DNA analysis for monitoring and stratification of patients with small cell lung cancer (2016) (0)
583 PI3-kinase inhibition enhances ABT-737 induced apoptosis in colorectal cancer cell lines (2010) (0)
The review presents strategies for fit-for-purpose method validation of biomarker assays to help ensure generation of robust data during clinical trials and to satisfy regulatory requirements. Fit-for-purpose biomarker method validation inanticancerdrugdevelopment (2010) (0)
Stromal Cell and Colonocyte EGFR Are Required for Efficient Tumor Xenograft Growth of Colon Cancer Cells (2011) (0)
A Phase II Study of Combined Cetuximab, Irinotecan, Oxaliplatin and Uft (ESCOUT) in Patients with Advanced Colorectal Cancer (ACRC) Incorporating Analysis of Circulating Tumour Cells (CTCS) (2012) (0)
Tissue and blood borne biomarkers in drug development: the view from an academic GCLP laboratory (2008) (0)
Predictive biomarkers for immunotherapy in lung cancer: Opportunities and challenges (2016) (0)
Neoantigen-directed immune escape in lung cancer evolution (2019) (0)
Abstract C184: Validation of an ELISA for the determination of Rituximab pharmacokinetics in clinical trials subjects (2009) (0)
Abstract 2874: Understanding small cell lung cancer metastasis using circulating tumor cell (CTC)-derived tumor explant (CDX) models (2021) (0)
Fully phosphorothioated second-generation 19-mer mixed-backbone antisense oligonucleotide (ASO) consisting of an 11-nucleotide DNA core flanked at the 3' and 5' ends by four 2'-O-methyl RNA residues, targeting the X-linked inhibitor of apoptosis protein (XIAP) (2009) (0)
Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells (2014) (0)
Preclinical development of xiapuradamib therapy for lung cancer (2006) (0)
Defining the Cytokine Storm – DECYST 01 (2022) (0)
Abstract CN02-02: CTCs as pharmacodynamic and /or predictive biomarkers (2009) (0)
Abstract 4408: Mutant ABL1 is a genetic dependency in non-small cell lung cancer amenable to pharmacological intervention (2016) (0)
A chromotographic screening method to identify agents that reverse intrinsic drug resistance in colon cancer cells (2006) (0)
Circulating and imaging biomarkers of chemotherapy-induced cardiotoxicity in cancer patients; a translational approach (2012) (0)
Report of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland. (2018) (0)
A novel PCR error correction algorithm for cell-free DNA next generation sequencing data using high performance computing (2016) (0)
C IRCULAT ING TUMOR CELLS (2012) (0)
Abstract IA27: Small cell lung cancer circulating tumor cell-derived explants: A new preclinical platform for examining drug response (2016) (0)
Abstract A176: RET inhibition: Development of novel compounds and a personalized medicine strategy in lung adenocarcinoma (2015) (0)
Abstract 6238: Profiling of the circulating cell-free DNA methylome for detection and subtyping of small cell lung cancers (2022) (0)
ABELSON TYROSINE KINASE ACTIVATION SUPPRESSES APOPTOSIS IN HEMATOPOIETIC-CELLS DEPRIVED OF INTERLEUKIN-3 (IL-3) OR TREATED WITH HYDROXYUREA (1993) (0)
Chronic anoxia results in downregulation of pro-apoptotic proteins of the Bcl-2 family in a panel of human colon carcinoma cell lines. (2002) (0)
Abstract IA29: Circulating Tumor Cells: A liquid biopsy for SCLC with multiple applications (2018) (0)
Assessment of the variability of and effect of hormone therapy on circulating tumor cell numbers and androgen receptor expression in patients with prostate cancer. (2012) (0)
New biomarkers - critical aspects of clinical evaluation (2009) (0)
Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2020) (0)
Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2020) (0)
Interrogating the precancerous evolution of pathway dysfunction in lung squamous cell carcinoma using XTABLE (2022) (0)
Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2020) (0)
Computer aided discovery of inhibitors of thymidine phosphorylase and Src (2007) (0)
Biomarkers in early clinical trials of pro-apoptotic drugs (2011) (0)
P59 Building a quality assurance (QA) system that is fit for purpose in an academic laboratory (2007) (0)
Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells (2014) (0)
Pancreatic circulating tumor cells: Where are they? (2012) (0)
Molecular profiling of circulating tumour cells (CTCs) in non-small cell lung cancer within the TRACERx study of intratumoural heterogeneity and evolution (2016) (0)
Blood-Based Cancer Biomarkers: Circulating Tumor Cells (2016) (0)
Drug Resistance and the Survival Niche (1999) (0)
Detection and molecular analysis of circulating tumour cells isolated from SCLC patients following short and long term storage (2016) (0)
ACTIVATED ABELSON TYROSINE KINASE EXPRESSION SUPPRESSES APOPTOSIS (1993) (0)
Abstract B49: “Triple wild-type” co-mutational profile in early-stage KRAS-mutant lung cancer (2020) (0)
9 Liquid biopsy in small cell lung cancer (SCLC) (2018) (0)
262 POSTER Pre-clinical evaluation of the novel alkylating agent RH1 against paediatric tumour cell lines (2006) (0)
427 POSTER Preclinical development of xiapuradamib therapy for lung cancer (2006) (0)
evaluation Of A Panel Of Circulating Biomarkers During Development Of Anthracycline-induced Cardiotoxicity In Lymphoma And Breast Cancer Patients : 446 (2015) (0)
MA22.03 SCLC Circulating Tumour Cell Derived Explants: The Clinical Characteristics of Patients Whose Samples Generate CDX (2018) (0)
494 Preliminary results from a phase I clinical trial of the bioreductive drug, RH1 (2004) (0)
The rodent non-genotoxic hepatocarcinogen nafenopin suppresses apoptosis preferentially in non-cycling hepatocytes, but elevates CDK4, a cell cycle progression factor (1998) (0)
397 Development of a doxycycline-dependent caspase 3 death switch model to assess the immune response to rapid and synchronous tumour cell apoptosis in vivo (2010) (0)
CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC) (2022) (0)
Activation of v-Abl tyrosine kinase suppresses apoptosis and regulates phosphorylation of protein kinase B (PKB) and the pro-apoptotic protein Bad (1999) (0)
Suppression of drug-induced apoptosis by B lymphoma micro-environmental survival signals (2000) (0)
Abstract 1732: PI3K inhibition potentiates ABT-737 induced apoptosis in colorectal cancer cells independent of MCL1 downregulation or AKT/mTOR inhibition. (2013) (0)
Circulating Tumour Cells, Utility Beyond Prognosis (2012) (0)
v-Abl mediated upregulation of p21WAF-1 in growth arrested and proliferating myeloid cells (1999) (0)
364 POSTER Obatoclax in SCLC: preclincal evaluation of a BH3 mimetic (2008) (0)
Abstract CN02-01: CTCs in small cell lung cancer: Biomarkers and biology. (2013) (0)
Bcr-Abl tyrosine kinase activity induces a loss of p53 protein that mediates a delay in differentiation (2000) (0)
Meeting Proceedings of the “Phase I: Where Science Becomes Medicine” Conference, Manchester, UK: Meeting Overview (2019) (0)
Abstract A185: Combining unbiased network analysis and cancer genomics to guide precision medicine-oriented early-phase clinical trials (2018) (0)
iRFP (near-infrared fluorescent protein) imaging of subcutaneous and deep tissue tumours in mice highlights differences between imaging platforms (2021) (0)
Phenotypic characterisation of a panel of SCLC circulating tumour cell derived explant models (CDX) (2016) (0)
Lineage plasticity in SCLC generates non-neuroendocrine cells primed for vasculogenic mimicry (2022) (0)
P2.13-33 A Case Report of Exceptional Clinical Response to MEK Inhibition in a Patient with NRAS Mutation Positive NSCLC (2018) (0)
Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells (2015) (0)
Cancer Therapy : Preclinical Activity of the Monocarboxylate Transporter 1 Inhibitor AZD 3965 in Small Cell Lung Cancer (2014) (0)
Pro-opiomelanocortin is a marker of liver and brain metastases from small cell lung cancer xenografts (2011) (0)
487 POSTER An inducible expression system to study the EGFR-T790M gefitinib-resistance mutation in a human lung cancer cell line (2008) (0)
Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (2020) (0)
Impact of lineage plasticity to and from a neuroendocrine phenotype on disease progression and response in prostate and lung cancers (2021) (0)
Association of circulating tumor cells with venous thromboembolism in advanced non-small cell lung cancer (2014) (0)
Application of quantitative digital tissue analysis software to perform automated characterisation of microlitered (ISET) circulating tumour cells in small cell lung cancer (2014) (0)
A conformational change in the pro-apoptotic protein Bak integrates diverse cellular damage signals (1999) (0)
Abstract IA05: Circulating tumor cells in lung cancer: Biomarkers, biology, and mouse models to study drug resistance (2015) (0)
Abstract 470: Application of sequencing, liquid biopsies and patient derived xenografts for personalized medicine in melanoma (2016) (0)
Changes in plasma biomarkers over time in patients (pts) with advanced biliary tract cancer (ABC) treated in the UK ABC-03 randomized phase II trial (2015) (0)
491 POSTER Trageting XIAP in paediatric cancers (2006) (0)
453 Validation of pharmacodynamic assays to determine the clinical effect of an antisense to the XIAP inhibitor of apoptosis (2004) (0)
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data (2019) (0)
Multiple uses of circulating tumor cells in lung cancer (2020) (0)
Micro-environmental survival stimuli combine to regulate Bcl-XL and Bax and suppress drug-induced apoptosis in B lymphoma cells (1999) (0)
SP-0104: DREAMtherapy trial of novel rectal chemoradiotherapy (2014) (0)
Phase I trial evaluating MEK inhibitor selumetinib with concomitant thoracic radiotherapy in non-small-cell lung cancer (2018) (0)
Activated c-Src expression correlates with high tumour grade, high proliferation and increased tumour size in invasive breast carcinoma and PTHrP receptor expression in breast cancer bone metastases. (2007) (0)
In silico screening of non-kinase inhibitors of c-Src-SH3: targeting protein-protein interactions (2007) (0)
Abstract IA19: Multiple uses of circulating tumor cells in lung cancer? (2020) (0)
The interaction between prognostic and pharmacodynamic biomarkers (2013) (0)
MS32.03 Liquid Biopsies for Drug Development in SCLC (2018) (0)
Identification and Verification of a Biomarker Panel for Early Diagnosis of Lung Cancer Patients (2018) (0)
First results from the phase I dual rectal angiogenesis MEK inhibition radiotherapy (DREAMtherapy) trial in locally advanced rectal cancer. (2012) (0)
Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial. (2023) (0)
Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study (2021) (0)
A Blood Borne Biomarker of Cell Death (nucleosomal DNA) Is An Early Predictor of End of Treatment Response to Chemotherapy in Lymphoma (2008) (0)
The impact of cytotoxic chemotherapy on imaging and circulating biomarkers of angiogenesis in colorectal cancer (2016) (0)
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of the bioreductive drug RH140 (2005) (0)
627 M30 AND M65 AS NOVEL BIOMARKERS IN ADVANCED PROSTATE CANCER (2009) (0)
Synthesis of the Novel Difluoro analogue of UCS15A and its Evaluation With Src (2006) (0)
Membrane Transport Dynamics (1996) (0)
Cancer Therapy: Preclinical Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer (2014) (0)
302 ORAL PCAF plays a key role in the regulation of the cellular fate in hypoxia (2007) (0)
Inhibition of Src for potential use in cancer chemotherapy (2007) (0)
Circulating tumor cells and circulating tumor microemboli from patients with small cell lung cancer show heterogeneity in epithelial to mesenchymal transition phenotype and evidence of vasculogenic mimicry (2013) (0)
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin (2018) (0)
102 POSTER Quantitative clinical biomarker measurement using multiplexed quantum dot immunhistochemistry (2008) (0)
Contribution of HIF-1 and drug penetrance to hypoxia- mediated oxaliplatin resistance in colorectal cancer spheroids (2007) (0)
Combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) analysis of blood from patients with pancreatic cancer (2016) (0)
Cell sensitivity assays. Quantitative detection of apoptotic cells in vitro using the TUNEL assay. (2001) (0)
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in precision-medicine oriented early phase clinical trials (2018) (0)
Effects of combining the potent Src inhibitor AZD0530 with conventional cytotoxic agents in colorectal cancer cells in vitro (2007) (0)
Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’ (2018) (0)
Abstract PL04-04: Developing circulating tumor cell derived explant models (CDX) (2016) (0)
Identification and Targetin g of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer Graphical (2016) (0)
Abstract CN07-01: Using CTCs to improve outcomes in SCLC: Single cell profiling, ex vivo cultures, and mouse models (2015) (0)
Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (2020) (0)
Downregulation of XIAP expression induces apoptosis and sensitizes a panel of pediatric tumor cells to cytotoxic agents (2007) (0)
EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC) (2022) (0)
The early detection of cancer. (1966) (0)
A new Alliance: biomedical societies in Europe unite to support research. (2011) (0)
P2.01-08 Clinical Trial in Progress: CONCORDE - A Phase 1B Study of Novel Agents in Combination with Conventional Radiotherapy in NSCLC (2019) (0)
Abstract 568: Nanonets for multiomics blood analysis and cancer biomarker discovery (2021) (0)
Hodgkin lymphoma 282 NODULAR SCLEROSIS-TYPE CLASSICAL HODGKIN LYMPHOMA IN THE ELDERLY: POOR PROGNOSIS AND HETEROGENEOUS NATURE NODE FOR NON-BULKY STAGE I-II PRELIMINARY RESULTS THE STANFORD G5 STUDY (2011) (0)
Hypoxia decreases expression of key Fas death receptor signalling components in human colon carcinoma cells: concomitant reduced response to Fas activating antibody. (2003) (0)
Establishment of CORONET: COVID-19 Risk in Oncology Evaluation Tool to Identify Cancer Patients at Low Versus High Risk of Severe Complications of COVID-19 Infection Upon Presentation to Hospital (2021) (0)
TIAM1-RAC1 Promote Survival of Small Cell Lung Cancer Cells Through Antagonizing Nur77-Induced BCL2 Conformational Change (2021) (0)
Spotlight on circulating tumour cells. (2017) (0)
Abstract 6150: AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models (2023) (0)
Abstract 3060: Circulating tumor cells from small cell lung cancer patients are tumorigenic (2014) (0)
Abstract 3155: Investigating chemoresistance in small cell lung cancer through the molecular profiling of single circulating tumour cells (2016) (0)
P2.05-058 Blood Biomarkers of Inflammation, Tumor Burden and Proliferation Predict Radiotherapy Response and Toxicity in Lung Cancer: Topic: Toxicities (2017) (0)
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (2020) (0)
Cardiotoxicity from cancer treatments: a translational approach to biomarker development (2014) (0)
Abstract 1769: Study of innate immune responses during small cell lung cancer (SCLC) development (2021) (0)
Circulating Melanoma Cells (CMCs), a potential biomarker? (2011) (0)
264 Vasculogenic mimicry in small cell lung cancer (2014) (0)
019 Chemotherapy-induced cardiotoxicity: could a translational cardiac MRI model help identify patients at risk? (2017) (0)
Molecular analysis of circulating tumour cells identifies distinct profiles in treatment naïve chemosensitive and chemorefractory small cell lung cancer patients (2016) (0)
OR2,4 The development of multi-dimensional models of serum IGF-I, -II, IGFBP-2 and -3 using artificial neural networks as “composite biomarkers” to predict colorectal cancer (2008) (0)
A vision of biomarkers and circulating tumour cells for the next decade (2013) (0)
SIGNALLING THROUGH CD40 SYNERGISES WITH BCL-2 TO DELAY DRUG INDUCED APOPTOSIS (1996) (0)
Abstract 601: Liquid biopsy-based precision medicine for extra-pulmonary neuroendocrine carcinomas (2021) (0)
Chronic hypoxia results in downregulation of proapoptotic proteins of the bcl-2 family in a panel of human colon carcinoma cells. (2001) (0)
437 PIM kinase inhibitor AZD1208 sensitises SCLC to BH3 mimetic AZD4320 (2014) (0)
Detection of EGFR and KRAS mutations in circulating free DNA in patients with operable non small cell lung cancer (NSCLC) (2009) (0)
143 POSTER Comparison of cell death ELISAs applied as potential surrogate biomarkers in the clinical evalution of AEG35156 (XIAP antisense) (2006) (0)

This paper list is powered by the following services:

Other Resources About Caroline Dive

en.wikipedia.org

What Schools Are Affiliated With Caroline Dive?

Caroline Dive is affiliated with the following schools:

Image Attributions

Image Source for Caroline Dive